Therapy Areas: AIDS & HIV
Merck Posts Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination with Doravirine in Adults With HIV-1 Infection
8 October 2020 - - US-based pharmaceutical company Merck (NYSE: MRK) has released Week 96 data from the Phase 2b trial (NCT03272347) evaluating the efficacy and safety of islatravir, the company's investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with doravirine (PIFELTRO), in treatment-naïve adults with HIV-1 infection, the company said.

Week 96 findings demonstrated that the combination of islatravir and doravirine maintained virologic suppression (as measured by the number of study participants achieving HIV-1 RNA levels
Login
Username:

Password: